ZA935942B - Controlled release tablets - Google Patents

Controlled release tablets

Info

Publication number
ZA935942B
ZA935942B ZA935942A ZA935942A ZA935942B ZA 935942 B ZA935942 B ZA 935942B ZA 935942 A ZA935942 A ZA 935942A ZA 935942 A ZA935942 A ZA 935942A ZA 935942 B ZA935942 B ZA 935942B
Authority
ZA
South Africa
Prior art keywords
hydrochloride
controlled release
release tablets
tablet
release
Prior art date
Application number
ZA935942A
Other languages
English (en)
Inventor
Jennie Sue Galloway Ludwig
Joel Elmore Sutton Jr
William Leroy Bass Jr
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10720358&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA935942(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ZA935942B publication Critical patent/ZA935942B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA935942A 1992-08-14 1993-08-13 Controlled release tablets ZA935942B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929217295A GB9217295D0 (en) 1992-08-14 1992-08-14 Controlled released tablets

Publications (1)

Publication Number Publication Date
ZA935942B true ZA935942B (en) 1995-02-13

Family

ID=10720358

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA935942A ZA935942B (en) 1992-08-14 1993-08-13 Controlled release tablets

Country Status (21)

Country Link
US (1) US5427798A (zh)
EP (1) EP0656775B1 (zh)
JP (1) JPH08500110A (zh)
KR (1) KR100294154B1 (zh)
AT (1) ATE161422T1 (zh)
AU (1) AU677595B2 (zh)
CA (1) CA2142320C (zh)
CY (1) CY2143B1 (zh)
DE (1) DE69316015T2 (zh)
ES (1) ES2111168T3 (zh)
GB (1) GB9217295D0 (zh)
GR (1) GR3025794T3 (zh)
HK (1) HK1004323A1 (zh)
IL (1) IL106693A (zh)
LU (1) LU90656I2 (zh)
MX (1) MX9304967A (zh)
NZ (1) NZ254947A (zh)
SG (1) SG43911A1 (zh)
TW (1) TW260607B (zh)
WO (1) WO1994004138A1 (zh)
ZA (1) ZA935942B (zh)

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5616344A (en) * 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
PT1017392E (pt) * 1997-09-25 2002-10-31 Bayer Ag Formulacao de medicamento com libertacao controlada do principio activo
US6221917B1 (en) 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5968553A (en) * 1997-12-30 1999-10-19 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
WO1999038504A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
JP2002501890A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの薬学的使用
WO1999038499A2 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
WO1999038503A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmacological uses of optically pure (+)-bupropion
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) * 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6589553B2 (en) * 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
USD430285S (en) * 1999-04-16 2000-08-29 Merck & Co., Inc. Tablet
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
IL149421A0 (en) * 1999-11-02 2002-11-10 Depomed Inc Pharmaceutical compositions containing fed mode inducing agents
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
CA2433915C (en) * 2001-02-08 2010-04-20 Andrx Pharmaceuticals, Inc. Improved controlled release oral dosage form
ITMI20011457A1 (it) * 2001-07-09 2003-01-09 Valpharma Sa Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US7109198B2 (en) * 2002-05-17 2006-09-19 Duke University Method for treating obesity
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2003284942A1 (en) * 2002-10-30 2004-06-07 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
US20040096497A1 (en) * 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) * 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
PT1575565E (pt) * 2003-08-08 2010-03-03 Biovail Lab Int Srl Comprimido de libertação modificada de cloridrato de bupropiona
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
KR20060128995A (ko) 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US8586085B2 (en) 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
GB0425445D0 (en) * 2004-11-18 2004-12-22 Smithkline Beecham Corp Novel compositions
KR100670798B1 (ko) 2004-12-17 2007-01-17 한국전자통신연구원 데이터베이스 캐시 시스템
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1896002A4 (en) * 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
EA200801081A1 (ru) * 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
US20070112075A1 (en) * 2005-10-14 2007-05-17 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007062228A1 (en) * 2005-11-28 2007-05-31 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
US20090291857A1 (en) * 2006-02-27 2009-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods to identify inhibitors of the unfolded protein response
JP2009529051A (ja) 2006-03-07 2009-08-13 オステオスクリーン アイピー， エルエルシー ＨＭＧＣｏ−Ａレダクターゼ阻害剤による骨および軟骨の強化
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2029135A4 (en) 2006-06-13 2011-08-17 Univ Leland Stanford Junior EPOXY HEMMER OF CYSTONE PROTEASES
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
WO2008023390A2 (en) * 2006-08-21 2008-02-28 Jubilant Organosys Limited Modified release pharmaceutical composition of bupropion hydrochloride
JP2010508997A (ja) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 減量薬を投与するための方法
TWI504419B (zh) 2006-11-09 2015-10-21 Orexigen Therapeutics Inc 層狀醫藥調配物
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
AR065989A1 (es) 2007-04-09 2009-07-15 Sepracor Inc Metodos y composiciones para el tratamiento de trastornos de la respiracion relacionados con el sueno
WO2008156749A1 (en) * 2007-06-18 2008-12-24 The General Hospital Corporation Combination therapy for depression
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
WO2009111031A2 (en) 2008-03-04 2009-09-11 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
HUE030803T2 (en) 2008-05-09 2017-06-28 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
AR077420A1 (es) 2009-07-22 2011-08-24 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
RU2616496C2 (ru) 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
EP2531176B1 (en) 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
JP5933553B2 (ja) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
JP2013539786A (ja) 2010-10-11 2013-10-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 置換ベンズアミドおよびその使用法
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
LT2736495T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
SG10201607685SA (en) 2011-11-21 2016-11-29 Calithera Biosciences Inc Heterocyclic inhibitors of glutaminase
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
CA2873701A1 (en) 2012-04-12 2013-10-17 Auckland Uniservices Limited Substituted benzamides and their uses
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
DK2858640T3 (da) 2012-06-06 2020-06-29 Nalpropion Pharmaceuticals Llc Sammensætning til anvendelse i en fremgangsmåde til behandling af overvægt og fedme hos patienter med høj cardiovaskulær risiko
SG11201503720SA (en) 2012-11-16 2015-06-29 Calithera Biosciences Inc Heterocyclic glutaminase inhibitors
US10100037B2 (en) 2013-03-15 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
JP6798890B2 (ja) 2014-06-13 2020-12-09 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤との併用療法
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
EP3212195A4 (en) 2014-10-31 2018-06-06 The Regents of The University of California Compositions and methods for treating hiv-associated cognitive dysfunction
CN107427477B (zh) 2015-03-10 2021-11-26 奥瑞基尼探索技术有限公司 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
JP2018520352A (ja) 2015-06-23 2018-07-26 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害するための組成物および方法
US10016471B2 (en) 2015-06-29 2018-07-10 Phloronol, Inc. Solid pharmaceutical compositions of brown algae
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3000996A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
CN108271371B (zh) 2015-10-30 2021-02-09 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
AU2016355429B2 (en) 2015-11-16 2021-05-06 Cerecor, Inc. Nucleic acid prodrugs
KR20180107232A (ko) 2016-02-12 2018-10-01 아스트라제네카 아베 오렉신 수용체 조정제로서의 할로-치환된 피페리딘
WO2017210565A1 (en) 2016-06-03 2017-12-07 Prisident And Fellows Of Harvard College Antifungal compounds
WO2018039612A1 (en) 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions and methods for promoting hair growth with mpc1 inhibitors
US10980767B2 (en) 2016-09-09 2021-04-20 The Regents Of The University Of California Estrogen receptor ligands, compositions and methods related thereto
US10472364B2 (en) 2016-09-09 2019-11-12 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
AU2017330443B2 (en) 2016-09-26 2023-08-24 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
PT3519050T (pt) 2016-09-28 2023-08-31 Medicon Pharmaceuticals Inc Composições para o tratamento de condições oftálmicas
BR112019006160A2 (pt) 2016-09-28 2019-06-18 Medicon Pharmaceuticals Inc composições e métodos para o tratamento das condições oftálmicas
MA46793A (fr) 2016-11-08 2019-09-18 Calithera Biosciences Inc Polythérapies faisant appel à un inhibiteur d'arginase
KR102579849B1 (ko) 2016-12-22 2023-09-18 칼리테라 바이오사이언시즈, 인코포레이티드 아르기나제 활성을 억제시키기 위한 조성물 및 방법
JP6984909B2 (ja) 2016-12-23 2021-12-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 活性ベースのプローブ化合物、組成物、および使用方法
BR112019014759A2 (pt) 2017-01-18 2020-03-03 Vanderbilt University Compostos heterocíclicos fundidos como inibidores seletivos de bmp
CA3053068A1 (en) 2017-02-24 2018-08-30 Merck Patent Gmbh 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
PT3600270T (pt) 2017-03-31 2023-07-25 Aurigene Discovery Tech Ltd Compostos e composições para tratar distúrbios hematológicos
US10994025B2 (en) 2017-05-12 2021-05-04 Massachusetts Institute Of Technology Argonaute protein-double stranded RNA complexes and uses related thereto
US11325943B2 (en) 2017-06-02 2022-05-10 Stealth Biotherapeutics Inc. Crystalline salt forms of SBT-20
EP3655379B1 (en) 2017-07-19 2023-04-05 California Institute of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
KR20200068659A (ko) 2017-10-11 2020-06-15 오리진 디스커버리 테크놀로지스 리미티드 3-치환된 1,2,4-옥사다이아졸의 결정질 형태
IL308364A (en) 2017-10-31 2024-01-01 Curis Inc Compounds and preparations for the treatment of hematological disorders
AU2018360386B2 (en) 2017-11-03 2023-11-09 Aurigene Oncology Limited Dual inhibitors of TIM-3 and PD-1 pathways
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
KR20200104335A (ko) 2017-12-22 2020-09-03 메디뮨 리미티드 Keap1의 BTB 도메인의 소분자 조절제
US10745400B2 (en) 2018-03-14 2020-08-18 Vanderbuilt University Inhibition of BMP signaling, compounds, compositions and uses thereof
WO2019200274A1 (en) 2018-04-12 2019-10-17 MatRx Therapeutics Corporation Compositions and methods for treating elastic fiber breakdown
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
EP3813841A4 (en) 2018-06-29 2022-03-09 The Regents Of The University Of California NEW MOLECULAR FORCEPS AGAINST NEUROLOGICAL DISORDERS AND VIRAL INFECTION
AU2019310595B2 (en) 2018-07-27 2022-11-24 1200 Pharma Llc CDK inhibitors and uses thereof
WO2020051322A1 (en) 2018-09-05 2020-03-12 The General Hospital Corporation Methods of treating cytokine release syndrome
AU2019364631A1 (en) 2018-10-26 2021-06-03 Keros Therapeutics, Inc. Crystal forms of an ALK2 inhibitor
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها
UA128041C2 (uk) 2019-01-25 2024-03-20 Браун Юніверсіті Спосіб лікування пов'язаного з віком запалення у пацієнта
WO2020160323A2 (en) 2019-01-31 2020-08-06 Elektrofi, Inc. Particle formation and morphology
EP3937935A1 (en) 2019-03-14 2022-01-19 Astrazeneca AB Lanabecestat for weight loss
EP3978076A4 (en) 2019-06-03 2023-02-22 Irimajiri Therapeutics Inc. CYCLIC AMIDE COMPOUNDS FOR THE TREATMENT OF RABIES AND METHOD THEREOF
CN114514035A (zh) 2019-09-13 2022-05-17 伊勒卓菲公司 递送用于治疗疾病的治疗性生物制剂的组合物和方法
KR20220100625A (ko) 2019-11-12 2022-07-15 젠자임 코포레이션 결핍된 cftr 활성에 의해 매개되는 질환 및 병태를 치료하기 위한 6원 헤테로아릴아미노설폰아미드
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021125800A1 (ko) 2019-12-16 2021-06-24 울산과학기술원 신생혈관형성인자의 억제를 위한 화합물 및 그 용도
US20230094393A1 (en) 2020-02-07 2023-03-30 Elektrofi, Inc. Peptide particles and methods of formation
US20230065628A1 (en) 2020-02-19 2023-03-02 Elektrofi, Inc. Droplet Formation and Particle Morphology
US20230181473A1 (en) 2020-04-17 2023-06-15 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration
WO2021263072A1 (en) 2020-06-25 2021-12-30 Dana-Farber Cancer Institute, Inc. Methods of treating disease
CN111830151B (zh) * 2020-07-01 2021-05-04 迪沙药业集团有限公司 盐酸安非他酮组合物质量控制用***适用性对照品
CA3191163A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
WO2022035805A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
EP4192811A1 (en) 2020-08-10 2023-06-14 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
US20230399304A1 (en) 2020-10-23 2023-12-14 Dana-Farber Cancer Institute, Inc. Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
US20240058344A1 (en) 2020-12-18 2024-02-22 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
US11571481B2 (en) 2020-12-21 2023-02-07 Cornell University Peptide-linked drug delivery system
WO2022150574A1 (en) 2021-01-08 2022-07-14 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
AU2022340880A1 (en) 2021-09-03 2024-03-07 Genzyme Corporation Indole compounds and methods of use
WO2023034946A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
IL311387A (en) 2021-10-01 2024-05-01 Nuvalent Inc Methods for solid tumor treatment using macrocyclic heteroaromatic ether compounds
CA3231813A1 (en) 2021-10-01 2023-04-06 Sibao CHEN Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023187422A1 (en) 2022-03-31 2023-10-05 Revolo Biotherapeutics Limited Compositions and their use in methods for treating intestinal inflammation
US20230322797A1 (en) 2022-04-07 2023-10-12 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023196910A1 (en) 2022-04-07 2023-10-12 Nuvalent, Inc Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
WO2023212721A1 (en) 2022-04-29 2023-11-02 Elektrofi, Inc. Injectable suspensions
WO2023223015A1 (en) 2022-05-16 2023-11-23 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating food allergies
WO2023250157A1 (en) 2022-06-24 2023-12-28 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
WO2024013209A1 (en) 2022-07-13 2024-01-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2024036098A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds
WO2024036097A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds and isotopologues thereof
WO2024073334A1 (en) 2022-09-26 2024-04-04 Rose Research Center, Llc Combination for use in a method of preventing weight gain
WO2024086634A1 (en) 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759838A (fr) * 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
CA948388A (en) * 1970-02-27 1974-06-04 Paul B. Hansen Pattern bonded continuous filament web
US4347257A (en) * 1979-10-09 1982-08-31 Burroughs Wellcome Co. Prolactin suppression in mammals
AU552261B2 (en) * 1980-01-21 1986-05-29 Wellcome Foundation Limited, The Use of propiophenone derivatives as adjuncts to benzo- diazepine tranquillisers
US4347176A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making same
US4355179A (en) * 1980-04-14 1982-10-19 Burroughs Wellcome Co. Radioactive nuclide labeled propiophenone compounds
US4347382A (en) * 1980-04-15 1982-08-31 Burroughs Wellcome Co. 3H Labeled compounds
US4347178A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making
US4347177A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making them
US4356165A (en) * 1980-04-14 1982-10-26 Burroughs Wellcome Co. Bupropion radioimmunoassay, and kit
US4425363A (en) * 1981-05-14 1984-01-10 Burroughs Wellcome Co. Treatment of tardive dyskinesia in mammals
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4393078A (en) * 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
US4438138A (en) * 1982-12-06 1984-03-20 Burroughs Wellcome Co. Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
DE3485618D1 (de) * 1984-08-17 1992-04-30 Wellcome Found Zusammensetzung zur kontrollierten abgabe eines wirkstoffes und ihre herstellung.
HUT69390A (en) * 1991-05-07 1995-09-28 Dynagen Inc Controlled, sustained release delivery system for smoking cessation

Also Published As

Publication number Publication date
IL106693A0 (en) 1993-12-08
JPH08500110A (ja) 1996-01-09
AU677595B2 (en) 1997-05-01
EP0656775A1 (en) 1995-06-14
ATE161422T1 (de) 1998-01-15
GB9217295D0 (en) 1992-09-30
EP0656775B1 (en) 1997-12-29
WO1994004138A1 (en) 1994-03-03
DE69316015T2 (de) 1998-04-16
KR950702827A (ko) 1995-08-23
CA2142320A1 (en) 1994-03-03
IL106693A (en) 1997-06-10
TW260607B (zh) 1995-10-21
HK1004323A1 (en) 1998-11-20
CA2142320C (en) 2001-10-09
MX9304967A (es) 1994-05-31
AU4725893A (en) 1994-03-15
CY2143B1 (en) 2002-06-21
KR100294154B1 (ko) 2001-09-17
NZ254947A (en) 1996-04-26
GR3025794T3 (en) 1998-03-31
SG43911A1 (en) 1997-11-14
US5427798A (en) 1995-06-27
LU90656I2 (fr) 2001-01-15
DE69316015D1 (de) 1998-02-05
ES2111168T3 (es) 1998-03-01

Similar Documents

Publication Publication Date Title
IL106693A0 (en) Controlled sustained release tablets
USD423259S (en) Mesh back chair
USD325542S (en) Earring
USD344889S (en) Child-proof tablet dispenser
USD390583S (en) Spotting scope
USD361594S (en) Art supply package
USD336183S (en) Mobile retail-display stand
USD336014S (en) Taco holder
USD361383S (en) Portable limb support
USD381396S (en) Push button faucet
USD334199S (en) Fuel dispenser
USD408753S (en) Article of jewelry
USD359554S (en) Tablet
USD356084S (en) Portable telephone
USD341038S (en) Chair
USD353077S (en) Party plate
USD356306S (en) Touchscreen stylus
USD286402S (en) Combination handset telephone and stand set
USD422815S (en) Smoothly contoured chair with cushions
USD347982S (en) Shut-off valve wrench
USD423260S (en) Mesh back chair with cushions
USD343995S (en) Tuna can press
USD365463S (en) Computer desk
USD382595S (en) Combined writing tablet and storage tray
USD275045S (en) Combined bed and control unit for an industrial oxygen concentrator or the like